annual Report 2009 - STRATEC Biomedical AG
annual Report 2009 - STRATEC Biomedical AG
annual Report 2009 - STRATEC Biomedical AG
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Report</strong> of the board of Management<br />
<strong>Report</strong> of the supervisory board<br />
THE share<br />
Corporate Governance<br />
Group Management report<br />
Consolidated financial statements<br />
Service<br />
Financial expenses are structured as follows:<br />
in v thousand IAS 39 categories* <strong>2009</strong> 2008<br />
Interest expenses on loan liabilities to banks<br />
(current and non-current) LMAC 195 199<br />
Interest expenses on typical silent partnerships LMAC 18 0<br />
Interest expenses on other current financial liabilities LMAC 1 25<br />
Total 214 224<br />
Other financial income/expenses include gains and losses on financial assets and financial liabilities measured at fair<br />
value and are structured as follows:<br />
in v thousand IAS 39 categories* <strong>2009</strong> 2008<br />
Gains / losses on financial assets measured at fair value<br />
through profit or loss:<br />
Interest and dividends 0 8<br />
Gains / losses on retirement 0 0<br />
Gains / losses on measurement at balance sheet date 361 -131<br />
Gains / losses on financial assets measured at fair value in equity:<br />
AHfT<br />
361 -123<br />
Interest and dividends 0 0<br />
Gains / losses on retirement 188 0<br />
Gains / losses on measurement at balance sheet date 0 -2,075<br />
Income / expenses on financial liabilities measured at fair value<br />
through profit or loss:<br />
AfS<br />
188 -2,075<br />
Interest and dividends 0 -52<br />
Gains / losses on retirement 0 63<br />
Gains / losses on measurement at balance sheet date 0 0<br />
LHfT<br />
0 11<br />
Total 549 -2,187<br />
* Reference is made to the information provided in Section VII “Financial instruments / Risk management” with regard to the IAS 39 categories and the abbreviations<br />
used here. Changes upon measurement of available-for-sale financial instruments as of the balance sheet date must be recognized through profit or loss when the fair<br />
value shows a significant or permanent impairment.<br />
stratec Annual <strong>Report</strong> <strong>2009</strong><br />
95